Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul;20(4):578-585.
doi: 10.1016/j.jcf.2021.05.016. Epub 2021 Jun 17.

Review of Gastrointestinal Motility in Cystic Fibrosis

Sara Henen  1 , Christine Denton  2 , Jeff Teckman  3 , Drucy Borowitz  4 , Dhiren Patel  5
Affiliations
Free article
Review

Review of Gastrointestinal Motility in Cystic Fibrosis

Sara Henen et al. J Cyst Fibros. 2021 Jul.
Free article

Abstract

Gastrointestinal manifestations in patients with cystic fibrosis (CF) are extremely common and have recently become a research focus. Gastrointestinal (GI) dysfunction is poorly understood in the CF population, despite many speculations including the role of luminal pH, bacterial overgrowth, and abnormal microbiome. Nevertheless, dysmotility is emerging as a possible key player in CF intestinal symptoms. Our review article aims to explore the sequelae of defective cystic fibrosis transmembrane conductance regulator (CFTR) genes on the GI tract as studied in both animals and humans, describe various presentations of intestinal dysmotility in CF, review newer diagnostic motility techniques including intraluminal manometry, and review the current literature regarding the potential role of dysmotility in CF-related intestinal pathologies.

Keywords: Cystic fibrosis; GI motility; dysmotility; gastrointestinal; highly effective modulators; laxatives; motility.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors whose names are listed immediately below certify that they have NO affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.

Comment in